Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • ABBV-022
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP
    • FAP-IL12
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen will be attending the PEGS Europe Virtual Conference 

Nov 9, 2020 | 2020, Past Events

Philogen will be attending the PEGS Europe Virtual Conference from November 9 to 12, 2020. Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Presentation in the Tumor Microenvironment Session (Immunotherapy Stream) on November 10 with the...

Philogen will be attending the Next Generation Protein Therapeutics & Bioconjugates Summit 

Nov 2, 2020 | 2020, Past Events

Philogen will be attending the Next Generation Protein Therapeutics & Bioconjugates Summit from November 2 to 5, 2020. Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Lecture with the title: Cancer Therapy Using Antibody-Cytokine...

Philogen announces publication of malignant brain tumor study results in Science Translational Medicine

Oct 8, 2020 | 2020, Press Releases, Scientific

PRESS RELEASE

Philogen will be attending the World ADC Digital Conference

Sep 15, 2020 | 2020, Past Events

Philogen will be attending the World ADC Digital Conference from September 15 to 18, 2020. Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Plenary Lecture on: “Small Molecule-drug Conjugates (SMDCs) & ADCs: A Comparative...

Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity

Aug 20, 2020 | 2020, Press Releases, Scientific

Our co-founder and Chief Scientific Officer, Prof. Dario Neri will join Philogen in a full time capacity. His professional path is featured on the ETH Zurich web site. Read the full story here. Always ask the important questions

Philogen announces a publication

Jul 17, 2020 | 2020, Press Releases, Scientific

Philogen announces a publication entitled: “A microdosing study with 99mTc-PHC-102 for the SPECT/CT imaging of primary and metastatic lesions in renal cell carcinoma patients” Link to Paper
« Older Entries

Recent Posts

  • Philogen to attend the European Bispecific and Multispecific Antibody congress in Amsterdam on the 22nd and 23rd of February, 2023
  • Philogen to attend the 7th Annual Next-Gen Immuno-Oncology Conference congress in London on the 9th and 10th of March, 2023
  • 23 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 16 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • 09 gennaio 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it